Selected article for: "IFN response and robust control"

Author: Kumari G. Lokugamage; Adam Hage; Craig Schindewolf; Ricardo Rajsbaum; Vineet D. Menachery
Title: SARS-CoV-2 is sensitive to type I interferon pretreatment
  • Document date: 2020_3_9
  • ID: 2w0zr9c0_21
    Snippet: CoV is unable to inhibit a IFN-I preprimed response. In contrast, SARS-CoV had no evidence 110 for STAT1 phosphorylation in either IFN-I treated or untreated cells, illustrating robust control 111 over IFN-I induction pathways. Examining further, STAT1, IFIT2, and TRIM25, known ISGs (17), 112 had increased protein expression in the context of SARS-CoV-2 infection following IFN 113 pretreatment (Fig. 2) . Basal STAT1 and TRIM25 levels are reduced .....
    Document: CoV is unable to inhibit a IFN-I preprimed response. In contrast, SARS-CoV had no evidence 110 for STAT1 phosphorylation in either IFN-I treated or untreated cells, illustrating robust control 111 over IFN-I induction pathways. Examining further, STAT1, IFIT2, and TRIM25, known ISGs (17), 112 had increased protein expression in the context of SARS-CoV-2 infection following IFN 113 pretreatment (Fig. 2) . Basal STAT1 and TRIM25 levels are reduced during SARS-CoV and 114 SARS-CoV-2 infection relative to control likely due to the mRNA targeting activity of non-115 structural protein 1 (NSP1) (24). However, IFN-I treatment results in augmented protein levels 116

    Search related documents:
    Co phrase search for related documents